Titre : Mitomycine

Mitomycine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Fields
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitomycine : Questions médicales les plus fréquentes", "headline": "Mitomycine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitomycine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitomycine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mitomycines", "url": "https://questionsmedicales.fr/mesh/D008937", "about": { "@type": "MedicalCondition", "name": "Mitomycines", "code": { "@type": "MedicalCode", "code": "D008937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.473.412.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitomycine", "alternateName": "Mitomycin", "code": { "@type": "MedicalCode", "code": "D016685", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elise Champeil", "url": "https://questionsmedicales.fr/author/Elise%20Champeil", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu." } }, { "@type": "Person", "name": "Owen Zacarias", "url": "https://questionsmedicales.fr/author/Owen%20Zacarias", "affiliation": { "@type": "Organization", "name": "Department of Sciences, John Jay College of Criminal Justice, New York, NY 10019, United States." } }, { "@type": "Person", "name": "Maggie Zheng", "url": "https://questionsmedicales.fr/author/Maggie%20Zheng", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: maggie.zheng@jjay.cuny.edu." } }, { "@type": "Person", "name": "Timothy Snyder", "url": "https://questionsmedicales.fr/author/Timothy%20Snyder", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: timothy.snyder@jjay.cuny.edu." } }, { "@type": "Person", "name": "Gloria Proni", "url": "https://questionsmedicales.fr/author/Gloria%20Proni", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: gproni@jjay.cuny.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Humphrey visual field made easy for residents.", "datePublished": "2024-09-27", "url": "https://questionsmedicales.fr/article/39331457", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/IJO.IJO_2519_23" } }, { "@type": "ScholarlyArticle", "name": "Detection of post-stroke visual field loss by quantification of the retrogeniculate visual pathway.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35640329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jns.2022.120297" } }, { "@type": "ScholarlyArticle", "name": "Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37880406", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-45541-1" } }, { "@type": "ScholarlyArticle", "name": "Visual feedback in the lower visual field affects postural control during static standing.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35843008", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.gaitpost.2022.07.004" } }, { "@type": "ScholarlyArticle", "name": "Five-Year Visual Field Outcomes of the HORIZON Trial.", "datePublished": "2023-02-21", "url": "https://questionsmedicales.fr/article/36813144", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.02.008" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indoles", "item": "https://questionsmedicales.fr/mesh/D007211" }, { "@type": "ListItem", "position": 6, "name": "Indolequinones", "item": "https://questionsmedicales.fr/mesh/D045563" }, { "@type": "ListItem", "position": 7, "name": "Mitomycines", "item": "https://questionsmedicales.fr/mesh/D008937" }, { "@type": "ListItem", "position": 8, "name": "Mitomycine", "item": "https://questionsmedicales.fr/mesh/D016685" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitomycine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitomycine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-03", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitomycine", "description": "Comment la mitomycine est-elle administrée ?\nQuels tests sont nécessaires avant traitement ?\nLa mitomycine est-elle utilisée pour tous les cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nY a-t-il des contre-indications au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Visual+Fields&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitomycine", "description": "Quels sont les effets secondaires courants ?\nLa mitomycine cause-t-elle des douleurs ?\nQuels symptômes indiquent une réaction allergique ?\nPeut-elle affecter le système immunitaire ?\nQuels signes de toxicité doivent alerter ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Visual+Fields&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitomycine", "description": "Comment minimiser les effets secondaires ?\nDes vaccinations sont-elles nécessaires ?\nComment éviter les infections pendant le traitement ?\nY a-t-il des recommandations alimentaires ?\nComment gérer le stress pendant le traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Visual+Fields&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitomycine", "description": "La mitomycine est-elle utilisée seule ?\nQuelle est la durée du traitement ?\nComment surveiller l'efficacité du traitement ?\nQuels soins de soutien sont recommandés ?\nY a-t-il des interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Visual+Fields&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitomycine", "description": "Quelles sont les complications possibles ?\nLa mitomycine peut-elle causer des cancers secondaires ?\nComment gérer une toxicité sévère ?\nQuels tests pour surveiller les complications ?\nY a-t-il des effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Visual+Fields&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitomycine", "description": "Qui est à risque d'effets secondaires ?\nLes antécédents de cancer augmentent-ils le risque ?\nLe tabagisme influence-t-il le traitement ?\nY a-t-il des facteurs génétiques à considérer ?\nL'âge influence-t-il la tolérance au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Visual+Fields&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la mitomycine est-elle administrée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La mitomycine est généralement administrée par injection intraveineuse ou intravésicale." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant traitement ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont souvent requis pour évaluer la santé du patient." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée pour tous les cancers ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement utilisée pour des cancers spécifiques comme le cancer de la vessie." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont surveillés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs comme le CA 19-9 peuvent être surveillés selon le type de cancer traité." } }, { "@type": "Question", "name": "Y a-t-il des contre-indications au traitement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies rénales peuvent être des contre-indications." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, et fatigue." } }, { "@type": "Question", "name": "La mitomycine cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des douleurs abdominales ou des douleurs au site d'injection." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réaction allergique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des démangeaisons, éruptions cutanées ou difficultés respiratoires peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Peut-elle affecter le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut réduire les globules blancs, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels signes de toxicité doivent alerter ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements inhabituels ou des ecchymoses peuvent indiquer une toxicité." } }, { "@type": "Question", "name": "Comment minimiser les effets secondaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hydratation et des médicaments antiémétiques peuvent aider à réduire les effets secondaires." } }, { "@type": "Question", "name": "Des vaccinations sont-elles nécessaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement." } }, { "@type": "Question", "name": "Comment éviter les infections pendant le traitement ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les foules et pratiquer une bonne hygiène peut aider à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en nutriments est recommandée pour soutenir le traitement." } }, { "@type": "Question", "name": "Comment gérer le stress pendant le traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation et le soutien psychologique peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée seule ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être utilisée seule ou en combinaison avec d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Quelle est la durée du traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La durée varie selon le type de cancer, mais elle est souvent administrée sur plusieurs cycles." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des examens d'imagerie et des tests sanguins réguliers sont utilisés pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels soins de soutien sont recommandés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des soins de soutien comme la gestion de la douleur et des conseils nutritionnels sont recommandés." } }, { "@type": "Question", "name": "Y a-t-il des interactions médicamenteuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut interagir avec d'autres médicaments, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des infections, des saignements et des problèmes rénaux." } }, { "@type": "Question", "name": "La mitomycine peut-elle causer des cancers secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation de mitomycine peut augmenter le risque de cancers secondaires à long terme." } }, { "@type": "Question", "name": "Comment gérer une toxicité sévère ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation et un traitement symptomatique peuvent être nécessaires en cas de toxicité sévère." } }, { "@type": "Question", "name": "Quels tests pour surveiller les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins réguliers et des examens d'imagerie sont nécessaires pour surveiller les complications." } }, { "@type": "Question", "name": "Y a-t-il des effets à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des effets à long terme peuvent inclure des problèmes pulmonaires ou rénaux, nécessitant un suivi." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des antécédents médicaux complexes sont plus à risque." } }, { "@type": "Question", "name": "Les antécédents de cancer augmentent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de cancer peuvent augmenter le risque d'effets secondaires lors du traitement." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter l'efficacité du traitement et augmenter les risques d'effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent influencer la réponse au traitement par mitomycine." } }, { "@type": "Question", "name": "L'âge influence-t-il la tolérance au traitement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients plus âgés peuvent avoir une tolérance réduite aux effets de la mitomycine." } } ] } ] }

Sources (10000 au total)

Humphrey visual field made easy for residents.

Visual field testing is an indispensable part of the assessment of glaucoma. Of paramount importance to both the practitioner and the perimetrist is the guidance on how to conduct the test to get the ... To simplify the basics of understanding single-field analysis of visual field tests by using the Humphrey perimeter.... The general principle and a brief overview of how the Humphrey visual field is conducted and the approach to interpreting the results of single field analysis in an easy-to-understand manner are prese... This educational video is an attempt to simplify the interpretation of Humphrey visual field single-field analysis with illustrations and video clips that would be useful to practicing ophthalmologist... https://youtu.be/x8iZLDR4XdY....

Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.

We investigated the relationship between foveal avascular zone (FAZ)-related parameters, assessed by optical coherence tomography angiography (OCT-A), and visual field (VF) progression in early-stage ...

Visual feedback in the lower visual field affects postural control during static standing.

The dorsal parietal visual system plays an important role in self-motion perception and spatial cognition. It also strongly responds to visual inputs from the lower visual field. Postural control is m... Do visual stimuli presented to the lower and upper visual fields affect postural control and sensory reweighting?... Twenty-nine healthy young adults participated in the study. Four conditions (full visual field, upper visual field, lower visual field, and no optic flow condition) were simulated in a VR environment ... Optic flow in the full and lower visual fields produced significantly smaller 95 % ellipse area and RMS of COP in the anterior-posterior direction compared to optic flow in the upper visual field. Furth... Visual feedback affects static postural control more when presented in the lower visual field compared to the upper visual field....

Five-Year Visual Field Outcomes of the HORIZON Trial.

To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS).... Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial.... A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery. W... Data from 352 eyes in the CS-HMS arm and 165 in the CS arm were analyzed (2966 VFs). The mean RoP was -0.26 dB/y (95% credible interval -0.36, -0.16) for CS-HMS and -0.49 dB/y (95% credible interval -... CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors....

Effect of trabeculectomy on the rate of progression of visual field damage.

This study quantifies the effect of trabeculectomy on the rate of progression (RoP) of visual field (VF) damage utilising pre- and post-operative visual function as the outcome instead of surrogate ou... Clinical and VF data from 199 sequential patients who underwent trabeculectomy between 2015 and 2016 were extracted from the network of sites of Moorfields Eye Hospital NHS Foundation Trust. Of these,... We analysed 10 [9,12] VFs per subject (Median [Interquartile Range]). At surgery, the age was 67 [57, 72] years, mean deviation was -10.84 [-14.7, -5.6] dB and the IOP was 18 [15, 20] mmHg. One year a... Trabeculectomy leads to a significant reduction in the RoP of VF loss postoperatively....

A Consensus Statement on the Terminology for Automated Visual Field Abnormalities.

A multitude of terms have been used to describe automated visual field abnormalities. To date, there is no universally accepted system of definitions or guidelines. Variability among clinicians create... In phase one of the study, all neuro-ophthalmologists in Israel were asked to complete a survey in which they described the abnormalities in 10 selected automated visual field tests. In phase 2 of the... Twenty-six neuro-ophthalmologists participated in the initial survey. On average, there were 7.5 unique descriptions for each of the visual fields (SD 3.17), a description of only the location in 24.6... The study confirmed a great degree of variability in the use of terminology to describe automated visual field abnormalities. The creation of a consensus statement was associated with improved use of ...

Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.

To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs.... Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation di... There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movem... Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. ...

Peripheral visual field loss and activities of daily living.

Peripheral visual field (VF) loss affects 13% of the population over 65. Its effect on activities of daily living and higher order visual processing is as important as it is inadequately understood. T... In this review, glaucoma and retrochiasmal cortical damage are utilized as examples of peripheral field loss which typically spare central vision and have patterns respecting the horizontal and vertic... Peripheral VF loss is an under-recognized cause of patient distress and disability. All peripheral field loss is not the same, differential patterns of loss affect parameters of activities of daily li...